Pharmacogenetics of endocrine therapy for breast cancer

The selective estrogen receptor modulator tamoxifen has been used for more than three decades for the treatment, and more recently prevention, of breast cancer in women of all ages. The conversion of tamoxifen to active metabolites involves several cytochrome P450 (CYP) enzymes. CYP2D6 is the key en...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annual review of medicine 2011-01, Vol.62 (1), p.281-293
Hauptverfasser:	Higgins, Michaela J, Stearns, Vered
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidepressive Agents Antineoplastic Agents, Hormonal - therapeutic use Aromatase Inhibitors - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - epidemiology Breast Neoplasms - genetics Carcinoma - drug therapy Clinical Trials as Topic Contraindications Cytochrome P-450 CYP2D6 - genetics Drug Interactions - genetics Endocrine therapy Enzymes Estrogens Female Genes Genetics Hot Flashes - drug therapy Humans Metabolites Pharmacology Polymorphism, Single Nucleotide Receptors, Estrogen - antagonists & inhibitors Tamoxifen - metabolism Tamoxifen - therapeutic use Treatment Outcome Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!